Previous 10 | Next 10 |
Company entered into negotiations with third party to transfer lease obligation Non-binding letter of intent signed 60-day exclusivity period to finalize details A successful transaction would lead to a reduction in legacy infrastructure and associated costs MORRISVILLE, N...
Novan ( NOVN ) has completed the recruitment of ~680 subjects in its two pivotal Phase 3 clinical trials evaluating once-daily topical gel SB206 for the treatment of molluscum contagiosum. More news on: Novan, Inc., Healthcare stocks news, Read more ...
MORRISVILLE, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has recently completed patient recruitment in the Company’s ongoing “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesion...
Preclinical data published in Antiviral Research Study conducted by Drs. N.S. Banerjee, L.T. Chow and T.R. Broker at The University of Alabama at Birmingham Findings reinforce anti-viral mechanism of action for Novan’s nitric oxide-based drug substance HPV-related clinic...
More than 50 percent of total expected patients now enrolled Virtually all of the clinical sites now active Discipline and execution focus remain of equal importance to recruitment activity MORRISVILLE, N.C., July 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Nova...
The following slide deck was published by Novan, Inc. in conjunction with this Read more ...
Expansion of the existing relationship with MedPharm around formulation science Manufacturing agreement established for production of proprietary drug substance Partner network now includes those located in the UK, Switzerland, Finland, Japan and the US MORRISVILLE, N.C., June ...
MORRISVILLE, N.C., June 13, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the 2019 JMP Securities Life Sciences Conference in New York on Thursday, June 20, 2019. Participation will include a fireside chat as well a...
MORRISVILLE, N.C., June 06, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today announced it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(b)(2)(A). This rule requires a ...
Novan (NASDAQ: NOVN ) has dosed first patient in its “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 program, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum. More news on: Novan, Inc., H...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...